Since anti‐PD‐1/PD‐L1 monotherapy has resulted in durable tumor responses and improved clinical outcomes when used alone or in combination with other therapies,2, 52 these agents are more widely applicable in clinical practice. Here, CD274 is linked to neoplasm.